PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cell Cycle. Author manuscript; available in PMC 2010 June 16.
Published in final edited form as:
Published online 2007 December 18.
PMCID: PMC2886808
NIHMSID: NIHMS205038

Interleukin-2 receptor downstream events in regulatory T cells

Implications for the choice of immunosuppressive drug therapy

Abstract

Naturally occurring CD4+CD25highFOXP3+ regulatory T cells (Tregs) constitute a powerful mechanism of immune regulation and therefore, have important therapeutic potential for disorders such as autoimmune diseases, allograft rejection and graft-versus-host disease. Disruption of the IL-2R signalling pathway by genetic defects of the interleukin (IL)-2 gene or components of the IL-2 receptor (R) complex results in severe T cell-mediated autoimmunity rather than immunodeficiency, indicating a crucial role for IL-2R signalling for Treg development and function. Signalling downstream of the IL-2R can act through the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway, the Janus kinase (JAK)/Signal transducers and Activators of Transcription (STAT) pathway and the mitogen-activated protein kinase (MAPK) pathway. In this report we focus on the relevance of these pathways as well as the impact of immunosuppressive drugs that may affect or enhance Treg function by targeting IL-2R signalling.

Keywords: regulatory T cells, interleukin-2 receptor, rapamycin, cyclosporine A, mTOR pathway, Foxp3

Essential Role of IL-2 Signalling for Treg Function and Linkage to FOXP3 Expression

The high expression of the IL-2Rα chain (CD25) in naturally occurring CD4+CD25highFOXP3+ regulatory T cells (Treg)1 suggests that Tregs are more dependent on IL-2 for survival and function than CD4+CD25 T cells. This notion was later supported by several lines of evidence.24 When the IL-2 receptor (IL-2R) is engaged, heterodimerization of CD122 and CD132 follows, which activates the associated tyrosine kinases JAK1 and JAK3. The finding that a covalently linked JAK3 molecule can functionally replace the cytoplasmic domain of CD132 indicates that the role of this molecule in IL-2R signal transduction is the recruitment of JAK3.5 Conversely, CD122 provides essential docking sites for at least two major downstream mediators, the adaptor protein Shc and the transcription factor STAT5.57 In contrast to CD122, the role of CD25 appears to be confined to increasing binding affinity and it is postulated that the short cytoplasmic domain is unlikely to contribute to signal transduction.57 In line with the concept of IL-2 dependence of Treg, there are no Treg in IL-2-deficient mice,2,8,9 IL-2Rα (CD25)-deficient mice10 and IL-2Rβ-deficient mice.9,11 These studies in the murine system indicate that intact IL-2 signalling is requisite for the development and survival of Treg. Mechanistically it was shown that IL-2 directly regulates FOXP3 expression in human Treg and enhances the expansion of these cells in vivo.12,13 FOXP3 expression regulation involves the binding of STAT3 and STAT5 proteins to a highly conserved STAT binding site located in the first intron of the human FOXP3 gene.12 These data were complemented by studies in the murine system showing that Stat5a/b directly regulate FOXP3 expression.14 Consistent with this concept, recent data indicate an essential role for IL-2Rβ dependent JAK/STAT5 signaling for the development of Treg.15 These data reveal a critical link between IL-2 mediated JAK/STAT5 signaling and the maintenance of FOXP3 expression in Treg in mice as well as humans.16

IL-2R Downstream Events in Treg

In T cells, signalling downstream of the IL-2R can act through the PI3K/Akt/mTOR, JAK/STAT and the MAPK pathways. In Treg as a subset of T cells, engagement of the IL-2R fails to activate downstream targets of PI-3K signalling pathway, including Akt, mTOR or p70s6kinase.1719 This observation has important therapeutic implications since the immunosuppressive drug rapamycin (RAPA) targets the mTOR pathway. RAPA was shown to be useful for the expansion of Treg in vitro2022 and preserves the in vivo suppressive effects of Treg.23 These altered IL-2R PI-3 kinase downstream events may account for the hypoproliferative response of Tregs to IL-2 and are mediated through the inhibitory effect of PTEN (phosphatase and tensin homolog deleted on chromosome 10).24 Elegant studies by Walsh and colleges have demonstrated that targeted deletion of the lipid phosphatase PTEN using the Cre/Lox system allowed for expansion of Treg ex vivo in response to IL-2 without other stimuli.24 It was noteworthy that PTEN deficiency did not interfere with the thymic development or the function of Treg as evidenced in a colitis model.24 Based on these findings, we analyzed the relevance of PTEN for the relative resistance of Treg towards mTOR inhibition and found that expression levels of PTEN were rapidly downregulated in conventional CD4+CD25 (Tconv) T cells but not in Treg after stimulation.18 The physiological relevance of this finding may be that Tconv downregulate PTEN, as a negative regulator of T cell expansion, when they are activated which is supported by the observation that PTEN was shown to impose a requirement for CD28 costimulation in the presence of T cell receptor (TCR) stimulation, defining an important mechanism for its role in self-tolerance.25 Our findings that PTEN deficiency was associated with a reversal of the relative resistance of Treg towards mTOR inhibition is compatible with data from different tumor models in which PTEN knockdown sensitizes established tumors to RAPA in vitro and in vivo.26 Mechanistically we identified a relative resistance towards RAPA in Treg based on reduced usage of the mTOR pathway and on functional PTEN in vivo.18

IL-2R signalling is primarily mediated through activation of JAK1 and JAK3 with subsequent phosphorylation and activation of STAT5.27 Interestingly, we found that Treg activation by alloantigen and IL-2 led to a preferential activity of the STAT5 pathway and promoted the preferential expansion of Treg and FOXP3 expression in the presence of the mTOR inhibitor RAPA whereas conventional CD4+CD25 T cells were much more impacted by RAPA. This notion is consistent with previous data indicating that RAPA-resistant proliferation of CD8+ T cell clones could be blocked by anti-IL-2 Abs, suggesting that some of the pathways parallel to the PI3K/mTOR pathway, in this case the STAT5 pathway, triggered by IL-2R signaling account for the antigen driven RAPA resistance.28 In addition, these findings are consistent with a previous report indicating that the ability of CD28 to promote efficient Treg generation requires neither an intact PI-3K-binding motif nor an intact Itk kinase-binding motif but does require an intact Lck-binding motif in the CD28 cytosolic tail.29 In concert, the in vitro and in vivo studies indicate that Treg survival is dependent on IL-2R-STAT5 pathway but not PI-3K pathway. Based on the presence of several STAT5B consensus sequences in the FOXP3 promotor, it was hypothesized that there is a critical linkage between IL-2 signaling/STAT5B and FOXP3 expression in Treg. Recent data demonstrated that IL-2 activated long-form (LF) STAT5 and sustained FOXP3 expression in Treg but not in Tconv.16 Importantly, blocking LF STAT5 activation with the JAK inhibitor (AG-490) significantly reduced FOXP3 expression in Treg.16 The concept of mTOR as compared to JAK3/STAT5 pathway usage is illustrated in Figure 1.

Figure 1
Signalling through growth factor receptors can activate the PI3K/Akt/mTOR pathway and the JAK3/STAT5 pathway. (A) Growth factor receptors first stimulate PI 3 kinase, and through inositol phosphates activate AKT which then phosphorylates mTOR. The phosphorylation ...

Regarding the relevance of the third pathway downstream of IL-2R, including activation of mitogen activated protein kinase 1/2 (MEK1/2), and extracellular signal-regulated kinase 1/2 (Erk1/2) in vitro studies demonstrated that CD3/CD28—mediated activation of Ras, MEK1/2 and Erk1/2 was impaired in Treg.30 This study also demonstrated that Tregs are blocked from cell cycle progression due to decrease of cyclin E and cyclin A and increase of p27kip1 (cyclin dependent kinase inhibitor).30 IL-2 induced sustained increase of cyclin E and cyclin A and prevented upregulation of p27kip1.30 Murine CD4+CD25+ Treg cells displayed reduced capacity to activate JNK but not extracellular signal-related kinase (ERK) or p38 MAPK following stimulation with PMA/ionomycin.31 Conversely, in vitro—expanded CD4+CD25+ Treg cell lines derived from human cord blood showed normal activation of AKT but significantly reduced activation of Ras, MAP kinase kinase (MEK)1/2 and ERK1/2 upon TCR-mediated activation.30

Impact of Exemplary Immunosuppressive Drug Groups on Treg Physiology

Calcineurin inhibitor cyclosporine A

It was shown in the mouse model that one critical requirement for Treg function and expansion is calcineurin dependent IL-2 production, which is impacted by the calcineurin inhibitor cyclosporine A (CSA).23 In light of the finding that the interaction between NFATc and FOXP3 is required for the suppressive effects of Treg cells32,33 interference with NFAT by CSA may also contribute to the observed effects of CSA on Treg biology. Mechanistically it was demonstrated that CSA affects Treg development, expansion and graft-versus-host disease (GvHD) suppressor function in mice.23,34,35 In a murine skin graft model, CSA interfered with the de novo conversion of Tconv into alloantigen-specific Treg.36 In vitro studies on human cells suggested that CSA affects the highly suppressive subpopulation of human CD27+ Treg.37 Clinical data indicated that CSA treatment of patients undergoing renal allograft transplantation, reduced Treg frequencies as compared to other immunosuppressive regimens.3840 In the setting of pulmonary allotransplantation immunosuppression with tacrolimus (FK506) was superior to CSA with respect to Treg frequencies.41 The studies on the impact of CSA on Treg are detailed in Table 1.

Table 1
Impact of CSA as compared to RAPA on Treg function

mTOR inhibitor Rapamycin

The initial step during the biological action of RAPA is the binding to the intracellular immunophilin FK506-binding protein (FKBP12) which resembles calcineurin inhibitors.42 In contrast to the calcineurin inhibitors, RAPA does not inhibit TCR-induced calcineurin activity but the RAPA-FKBP12 complex inhibits the serine/threonine protein kinase mTOR, the activation of which is required for protein synthesis and cell cycle progression (Fig. 1). Therefore, RAPA blocks signalling in response to cytokines/growth factors, whereas calcineurin inhibitors exert their inhibitory effects by blocking TCR-induced activation.42 In vitro studies demonstrated that RAPA enables in vitro expansion of functionally suppressive Treg of murine20 or human21,22,43 origin (Table 1). Mechanistically different groups have suggested the the beneficial effect of RAPA is through selective Treg expansion,20 conversion of CD4 T cells into Treg22 and improved survival of Treg as compared to Tconv.43 In vivo the presence of RAPA allowed for the expansion and effector function of Treg in a GvHD model18,23 and the combination of RAPA and IL-10 induced tolerance in a diabetes model.44 Furthermore, a synergistic effect between Treg and RAPA has been demonstrated in a model of bone marrow graft rejection45 and GvHD.18 Differential expansion kinetics of Treg and Tconv in the presence of RAPA were based on a relative resistance towards RAPA in Treg based on reduced usage of the mTOR pathway and on functional PTEN as a negative regulator of the mTOR pathway.18

Mycophenolat mofetil

Preclinical studies demonstrate that MMF contributes to the generation of Treg and enhances their activity.46 However, in these studies MMF was combined with 1α,25-dihydroxyvitamin D3 in a diabetes model. Therefore, no direct evidence that the expansion of CD4+CD25+ cells was due to either MMF or 1α,25-dihydroxyvitamin D3 was provided.46 Recent in vitro studies on murine Treg indicate that MMF did not interfere with expansion and suppressor function of Treg in the presence of alloantigen stimulation.47 In human renal allograft recipients, the use of MMF and calcineurin inhibitor sparing was associated with increased Treg frequencies.48

Corticosteroids

Dexamethasone (DEX) induces cell death in T cells and could have unfavorable effects on Treg. However, Treg were shown to express higher levels of glucocorticoid receptor and Bcl-2, which coincided with an increased resistance to DEX-mediated cell death as compared to CD4+CD25 T cells.49 In the murine system, the administration of DEX to BALB/c mice enhances the proportion of Treg and the ratio of Treg/CD4+CD25 cells in the lymphoid organs, especially in the thymus. This correlates with the in vitro observation that Tregs express higher levels of glucocorticoid receptor.49 Furthermore, IL-2 selectively protected Treg from DEX-induced cell death, while IL-7 and IL-15 did not exert such preferential protective effects.49 Consistent with this concept, the steroid fluticasone propionate increased Treg mediated suppression of allergen-stimulated T effector cells through an IL-10-dependent mechanism50 and inhaled or systemic glucocorticoids have been found to induce FOXP3 and IL-10 expression and generation of Tregs.51 Further evidence that steroid treatment is compatible with intact Treg functions comes from studies on myasthenia gravis patients showing that the number of Treg cells in the blood is significantly lower in untreated myasthenia gravis patients than in age-matched healthy subjects, whereas it is normal or elevated in patients receiving prednisone (+/−azathioprine).52

Novel agents and monoclonal Abs

Anti-TNF mAb

Increased secretion of TNF, along with IL-1 and IL-6, is important in the pathogenesis of GvHD and rheumatoid arthritis (RA). Increased apoptosis of Tregs in patients with active RA is reduced by anti-TNF mAb infliximab.53 This is consistent with data indicating that TNF downmodulates the in vivo function of Treg.54

FK778

Recent data from a human allogeneic in vitro model indicate that the immunosuppressive drug FK778, induces regulatory activity in stimulated human CD4+CD25 T cells.55 Treg induced by FK778 displayed potent suppressor activity in a cell-cell contact-dependent manner; were CD25high, CD45RO+, CD27, CTLA-4+, GITR+ and FOXP3+.55

FTY720

The sphingosine-1-phosphate analogue FTY720 has shown promising immunomodulatory properties based on its pronounced effects on lymphoid migration. One could speculate that FTY720 may interfere with Treg function since it abrogates S1P/S1P1-dependent egression of lymphoid cells from lymphoid organs and in light of the fact that Treg express S1P which appears to be required for optimal suppression of effector T cell activities.56 In contrast it has been shown that FTY720 does not block the sequestration of Treg and importantly, increases their functional activity in a murine model of suppression of OVA-induced airway inflammation.57 Furthermore, data from a different mouse model indicates that FTY720 does not impair Treg mediated suppression of GvHD.58

Conclusions

Multiple studies have shown that Treg play a critical role in the maintenance of self tolerance, control of autoimmune diseases, transplant rejection and cancer.59 In order to modify Treg activity depending on the disease setting, the choice of immunosuppression is critical. Different studies have contributed to delineate the relevance of the IL-2R downstream events, and it is increasingly recognized that in contrast to conventional T cells, Treg have reduced mTOR pathway activity. Conversely, signalling through the JAK3/STAT5 pathway enhances Treg FOXP3+ expression and is crucial for Treg development. In conclusion immunossuppressants that target the mTOR pathway such as sirolimus or everolimus seem favorable for sparing Treg function in vivo. However, corticosteroids and novel agents that act independent of the IL-2R pathway also hold promise for a combination with Treg mediated suppressor function.

Acknowledgments

This report was supported by grants from the National Institute of Health (NIH; RO1 CA0800065 and P01 HL075462 to R.S.N.) and by the Deutsche Krebshilfe (Dr. Mildred-Scheel-Stiftung), Bonn, Germany (grant#108034 to R.Z.). We apologize to those whose work was not cited due to space limitations.

References

1. Stephens LA, Mottet C, Mason D, Powrie F. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol. 2001;31:1247–54. [PubMed]
2. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004;172:3983–8. [PubMed]
3. Furtado G, de Lafaille MAC, Kutchukhidze N, Lafaille JJ. Interleukin-2 signaling is required for CD4+ regulatory T-cell function. J Exp Med. 2002;196:851–7. [PMC free article] [PubMed]
4. Thornton A, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol. 2004;172:6519–23. [PubMed]
5. Nelson BH, McIntosh BC, Rosencrans LL, Greenberg PD. Requirement for an initial signal from the membrane-proximal region of the interleukin 2 receptor gamma(c) chain for Janus kinase activation leading to T cell proliferation. Proc Natl Acad Sci USA. 1997;94:1878–83. [PubMed]
6. Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. The structure of interleukin-2 complexed with its alpha receptor. Science. 2005;308:1477–80. [PubMed]
7. Lin JX, Leonard WJ. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev. 1997;8:313–32. [PubMed]
8. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature. 1991;352:621–4. [PubMed]
9. Malek T, Yu A, Vincek V, et al. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity. 2002;17:167–70. [PubMed]
10. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity. 1995;3:521–30. [PubMed]
11. Malek T, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Immunol Rev. 2004;4:665–70. [PubMed]
12. Zorn E, Nelson EA, Mohseni M, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006;108:1571–9. [PubMed]
13. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood. 206(107):2409–14. [PubMed]
14. Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, Watford WT, Laurence A, Robinson GW, Shevach EM, Moriggl R, Hennighausen L, Wu C, O’Shea JJ. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood. 2007;109:4368–75. [PubMed]
15. Burchill M, Yang J, Vogtenhuber C, Blazar BR, Farrar MA. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol. 2007;178:280–90. [PubMed]
16. Murawski MR, Litherland SA, Clare Salzler MJ, Davoodi Semiromi A. Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis. Ann N Y Acad Sci. 2006;1079:198–204. [PubMed]
17. Bensinger S, Walsh PT, Zhang J, Carroll M, Parsons R, Rathmell JC, Thompson CB, Burchill MA, Farrar MA, Turka LA. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol. 2004;172:5287–96. [PMC free article] [PubMed]
18. Zeiser R, Leveson Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J, Hou JZ, Negrin RS. Differential impact of mTOR inhibition on CD4+CD25+Foxp3+ regulatory T cells as compared to conventional CD4+ T cells. Blood. 2007 doi: 10.1182/blood-2007-06-094482. [PubMed] [Cross Ref]
19. Crellin NK, Garcia NV, Levings MK. Altered activation of AKT is required for the suppressive function of CD4+CD25+ T regulatory cells. Blood. 2006;109:2014–22. [PubMed]
20. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005;105:4743–8. [PubMed]
21. Battaglia M, Stabilini A, Migliavacca B, Horejs Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006;177:8338–47. [PubMed]
22. Valmori D, Tosello V, Souleimanian NE, Godefroy E, Scotto L, Wang Y, Ayyoub M. Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4 T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4 T Cells. J Immunol. 2006;177:944–9. [PubMed]
23. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, Contag CH, Negrin RS. Inhibition of CD4+CD25+ regulatory T cell function by calcineurin dependent interleukin-2 production. Blood. 2006;108:390–9. [PubMed]
24. Walsh P, Buckler JL, Zhang J, Gelman AE, Dalton NM, Taylor DK, Bensinger SJ, Hancock WW, Turka LA. PTEN inhibits IL-2 receptor-mediated expansion of CD4 CD25 Tregs. J Clin Invest. 2006;116:2521–31. [PMC free article] [PubMed]
25. Buckler J, Walsh PT, Porrett PM, Choi Y, Turka LA. Cutting edge: T cell requirement for CD28 costimulation is due to negative regulation of TCR signals by PTEN. J Immunol. 2006;177:4262–6. [PubMed]
26. Wendel H, Malina A, Zhao Z, Zender L, Kogan SC, Cordon Cardo C, Pelletier J, Lowe SW. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. 2006;66:7639–46. [PubMed]
27. Frank D, Robertson MJ, Bonni A, Ritz J, Greenberg ME. Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci USA. 1995;92:7779–83. [PubMed]
28. Slavik JM, Lim DG, Burakoff SJ, Hafler DA. Uncoupling p70(s6) kinase activation and proliferation: rapamycin-resistant proliferation of human CD8(+) T lymphocytes. J Immunol. 2001;166:3201–9. [PubMed]
29. Tai X, Cowan M, Feigenbaum L, Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol. 2005;6:152–62. [PubMed]
30. Li L, Godfrey WR, Porter SB, Ge Y, June CH, Blazar BR, Boussiotis VA. CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood. 2005;106:3068–73. [PubMed]
31. Su L, Creusot RJ, Gallo EM, et al. Murine CD4+CD25+ regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene. J Immunol. 2004;173:4994–5001. [PubMed]
32. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF, Mathis D, Benoist C, Chen L, Rao A. FOXP3 Controls Regulatory T Cell Function through Cooperation with NFAT. Cell. 2006;126:375–87. [PubMed]
33. Ho L, Crabtree G. A Foxy tango with NFAT. Nat Immunol. 2006;7:906–8. [PubMed]
34. Coenen J, Koenen HJ, van Rijssen E, Kasran A, Boon L, Hilbrands LB, Joosten I. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4(+)CD25(+)FoxP3(+) T cells. Bone Marrow Transplant. 2007:12. epub. [PubMed]
35. Wang H, Zhao L, Sun Z, Sun L, Zhang B, Zhao Y. A potential side effect of cyclosporin A: inhibition of CD4(+)CD25(+) regulatory T cells in mice. Tranplantation. 2006;82:1484–92. [PubMed]
36. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant. 2007;7:1722–32. [PubMed]
37. Coenen JJA, Koenen HJM, van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and not Cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood. 2006;107:1018–23. [PubMed]
38. Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, Monteferrante G, Aiello S, Cassis L, Gotti E, Gaspari F, Cattaneo D, Perico N, Remuzzi G. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol. 2007;18:1007–18. [PubMed]
39. Segundo D, Ruiz JC, Izquierdo M, Fernandez Fresnedo G, Gomez Alamillo C, Merino R, Benito MJ, Cacho E, Rodrigo E, Palomar R, Lopez Hoyos M, Arias M. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation. 2006;82:550–57. [PubMed]
40. Ruggenenti P, Perico N, Gotti E, Cravedi P, D’Agati V, Gagliardini E, Abbate M, Gaspari F, Cattaneo D, Noris M, Casiraghi F, Todeschini M, Cugini D, Conti S, Remuzzi G. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation. 2007;84:956–64. [PubMed]
41. Warnecke G, Avsar M, Steinkamp T, Reinhard R, Niedermeyer J, Simon AR, Haverich A, Struber M. Tacrolimus versus cyclosporine induction therapy in pulmonary transplantation in miniature swine. Eur J Cardiothorac Surg. 2005;28:454–60. [PubMed]
42. Abraham R, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol. 1995;14:483–510. [PubMed]
43. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol. 2007;178:320–9. [PubMed]
44. Battaglia M, Stabilini A, Draghici E, Gregori S, Mocchetti C, Bonifacio E, Roncarolo MG. Rapamycin and Interleukin-10 Treatment Induces T Regulatory Type 1 Cells That Mediate Antigen-specific Transplantation Tolerance. Diabetes. 2006;55:40–9. [PubMed]
45. Steiner D, Brunicki N, Bachar Lustig E, Taylor PA, Blazar BR, Reisner Y. Overcoming T cell—mediated rejection of bone marrow allografts by T-regulatory cells: Synergism with veto cells and rapamycin. Exp Hematol. 2006;34:802–8. [PubMed]
46. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol. 2001;167:1945–53. [PubMed]
47. Lim DG, Joe IY, Park YH, Chang SH, Wee YM, Han DJ, Kim SC. Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells. Transplant Immunol. 2007;18:94–100. [PubMed]
48. Cicinnati VR, Yu Z, Klein CG, Sotiropoulos GC, Saner F, Malagó M, Frilling A, Gerken G, Broelsch CE, Beckebaum S. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients—assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther. 2007;26:1195–208. [PubMed]
49. Chen X, Murakami T, Oppenheim JJ, Howard OM. Differential response of murine CD4+CD25+ and CD4+CD25 T cells to dexamethasone-induced cell death. Eur J Immunol. 2004;34:859–69. [PubMed]
50. Dao Nguyen X, Robinson DS. Fluticasone propionate increases CD4CD25 T regulatory cell suppression of allergen-stimulated CD4CD25 T cells by an IL-10-dependent mechanism. J Allergy Clin Immunol. 2004;114:296–301. [PubMed]
51. Karagiannidis C, Akdis M, Holopainen P, Woolley NJ, Hense G, Ruckert B, Mantel PY, Menz G, Akdis CA, Blaser K, Schmidt Weber CB. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol. 2004;114:1425–33. [PubMed]
52. Fattorossi A, Battaglia A, Buzzonetti A, Ciaraffa F, Scambia G, Evoli A. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology. 2005;116:134–41. [PubMed]
53. Toubi E, Kessel A, Mahmudov Z, Hallas K, Rozenbaum M, Rosner I. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann N Y Acad Sci. 2005;1051:506–14. [PubMed]
54. Valencia X, Stephens G, Goldbach Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF down-modulates the function of human CD4+CD25hi T-regulatory cells. Blood. 2006;108:253–61. [PubMed]
55. Kreijveld E, Koenen HJ, Hilbrands LB, van Hooff HJ, Joosten I. The immunosuppressive drug FK778 induces regulatory activity in stimulated human CD4+CD25 T cells. Blood. 2007;109:244–52. [PubMed]
56. Wang W, Graeler MH, Goetzl EJ. Physiological sphingosine 1-phosphate requirement for optimal activity of mouse CD4+ regulatory T cells. FASEB J. 2004;18:1043–5. [PubMed]
57. Sawicka E, Dubois G, Jarai G, Edwards M, Thomas M, Nicholls A, Albert R, Newson C, Brinkmann V, Walker C. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J Immunol. 2005;175:7973–80. [PubMed]
58. Taylor PA, Ehrhardt MJ, Lees CJ, Tolar J, Weigel BJ, Panoskaltsis Mortari A, Serody JS, Brinkmann V, Blazar BR. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD) Blood. 2007;110:3480–8. [PubMed]
59. Shevach E. CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2:389–400. [PubMed]
60. Mantel P, Ouaked N, Ruckert B, Karagiannidis C, Welz R, Blaser K, Schmidt Weber CB. Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol. 2006;176:3593–602. [PubMed]